Trial Profile
Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin in Previously Untreated HER2 Overexpressing Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 15 Feb 2023 According to a Shanghai Henlius Biotech media release, company announced, acceptance of Biologics License Application from US FDA for proposed biosimilar trastuzumab HLX02, based on clinical data of this trial.
- 01 Jun 2022 Status changed from active, no longer recruiting to completed.
- 07 Apr 2021 Results evaluating the efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with metastatic breast cancer, published in the BioDrugs